Horizon Therapeutics PLC $ 76.06 1.79 (2.41%)
HZNP News and Headlines - Horizon Therapeutics PLC
To Our Shareholders:
CGM Mutual Fund increased 20.7% during the second quarter of 2020 compared to a return of 20.5% for the Standard and Poor's 500 Index (S&P 500 Index) and 2.9% for the ICE BofAML U.S. Corporate, Government and Mortgage Index*. For the first six months of the year, CGM Mutual Fund decreased -12.9%, the S&P 500 Index decreased -3.1% and the ICE BofAML U.S. Corporate, Government and Mortgage Index returned 6.3%.
In the wake of a stormy late February and March, the market experienced a surprisingly strong rebound in the second quarter of 2020. The rally was not
Growth focused investors may be interested in the following stocks, as their price-earnings ratios are below 20 and their earnings per share have grown significantly over the past year.
Horizon Therapeutics PLC
The first company that meets the above listed criteria is Horizon Therapeutics PLC (HZNP), an Irish biotech developer of treatments for patients affected by rare and rheumatic diseases.
The company’s trailing 12-month EPS increased to $3.02 as of the first quarter of 2020, up from 48 cents in the same quarter of 2019.
The price-earnings ratio is 18.57 (versus the industry median of 22.92) as of June 22.
If faced with the choice between invasive surgery versus a few shots, most would probably choose the latter, ophthalmologists included. Patients with bulging eyes from thyroid eye disease may finally have a long-term solution for their eye predicament in new injections specifically designed to alleviate the cause of the disease. And it looks as though the company behind it, Horizon Pharma (HZNP), may end up having the whole market to itself for a while.
It’s not a particularly huge market, but with 12 years of exclusivity ahead, nearly flawless efficacy and safety results showing fast action and no close competitors
Shares of Horizon Pharma PLC (HZNP) gained in Monday trading after the company reported financial results for its third quarter. EPS of 26 cents beat analysts' expectations by four cents and revenue of $271.6 million beat estimates by $11.86 million but declined 0.8% year over year.
“Our third-quarter results reflect our dedicated focus on execution, driven by 65 percent year-over-year growth of our diverse portfolio of rare disease medicines,” Chairman, President and CEO Timothy P. Walbert said.Â
Further, the gross profit margin reached 53.8%, down from 59.2% in the prior-year quarter. The non-GAAP gross profit margin was 89.6%, which
Julian Robertson (Trades, Portfolio) is considered the father of the hedge fund. He launched his firm Tiger Management in 1980 with $8 million and turned it into over $22 billion in the late 1990s. During the third quarter the guru’s largest sells were the following:
He reduced his stake in Delta Air Lines Inc. (DAL) by 82.11% with an impact of -5.58% on the portfolio.
The company provides scheduled air transportation for passengers and cargo throughout the U.S. and around the world. The company's business segments are airline and refinery. Third-quarter operating revenue decreased 5.6% with
Robertson’s most significant new buy in the fourth quarter was his investment in Teva Pharmaceutical Industries Ltd. (TEVA), an Israeli pharmaceutical company. Robertson purchased a 595,300-share stake for an average price of $61.94 per share. The deal had a 5.04% impact on Robertson’s portfolio.
Sheets Smith Wealth Management is a hedge fund based in North Carolina that, on its last quarterly 13F, reported a total value of its portfolio of $365 million, with an increase of 1.02% since the previous quarter. During Q2 2015 the investment professional bought 19 new stocks and increased 84 of its existing stakes. The following are the most heavily weighted buys during the quarter.
Horizon Pharma (HZNP) is currently reporting triple-digit year-to-date and one-year stock returns. As of Aug. 24, the company has a year-to-date stock return of 124.98% and a one-year stock return of 198.97%.
Recently the company has received a great deal of press for its acquisition attempt of Depomed (DEPO). In July, Depomed rejected Horizon Pharma’s most recent offer for a takeover which valued the company at $33 per share. Depomed has been unwilling to enter into negotiations for a merger of the two companies, and in July amongst various negotiation attempts also enacted a poison pill plan which blocks any
Steven Mandel’s hedge fund, Lone Pine Capital, on July 27 initiated a position in Horizon Pharma Plc (HZNP), according to GuruFocus Real Time Picks.
The purchase was for 8,353,668 shares, which represent 5.4% of the drug company.
Horizon Pharma, which has acquired four other companies in the past two years, is in the process of attempting to merge with Depomed Inc. (DEPO), a maker of neurology treatments. The July 7 proposal offered $29.25 per share for Depomed, a 42% premium to its closing share price the previous day. Horizon raised its offer price to $33 on
Wall Street climbed more than 1% on last Monday, carrying the upward momentum to the closing bell. Stock market rebounded from a sharp decline last week, helped by the deal making in healthcare sector and surge in energy shares. On March 30, Dow Jones industrial average gained 263.65 points, or by 1.5%, to 17,976.31, its biggest daily percentage gain since Feb 3. The S&P 500 index added 25.22 points, or rose by 1.22% to 2,086.24. The Nasdaq composite rose 56.22 points, or 1.15%, to 4,947.44.
The stocks in European markets followed the trend in the U.S. markets and also rallied.
Horizon Pharma (HZNP) said that pre-clinical data from an investigator initiated study demonstrated that treatment with murine interferon gamma, which is an analogue of interferon gamma-1b (ACTIMMUNE(R)), improved the signs of disease severity in a mouse model of Autosomal Dominant Osteopetrosis Type II, the most common form of osteopetrosis, a group of conditions characterized by an increased skeletal mass due to impaired bone and cartilage resorption.
HZNP's ACTIMMUNE, a biologically manufactured protein similar to one the body makes naturally to help prevent infection, is currently FDA-approved for use in two rare diseases. It is indicated to